ClinicalTrials.gg
CompletedNCT04527718Updated Nov 10, 2022

Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers

A Phase 1 interventional study of Placebo and 611 in Healthy, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-10.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2021, 5 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1 randomized, double blinded, placebo-controlled, single dose escalation study to evaluate the safety, tolerability, and PK of 611 in healthy volunteers.

Read the detailed description

Total duration of the study period per subject is about 4 months broken down as follows:

The screening period is up to 28 days, one dose treatment, and follow- up period is up to 71±7 days (90±9 days for Cohorts 1 and 2).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. is the lead sponsor of 59 studies on the registry; 22 are open to participants now.

First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and willing to sign the ICF
  2. Healthy male and female subjects, non-smokers, 18-55 years of age
  3. In the opinion of the investigator, with no significant medical history, and in good health.
  4. 19.0-32.0 kg/m2 and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females.
  5. Subjects are able to follow the study protocol and complete the trial.

Exclusion criteria

Exclusion Criteria:

  1. History of to similar drugs to 611 or their .
  2. Pregnant, or nursing females.
  3. HepBsAg or HepCAb positive.
  4. (HIV) positive.
  5. Positive urine drug screen, or cotinine test.
  6. Any reason which, in the opinion of the Qualified Investigator, would prevent the subject from participating in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Cohort 1

    611 dose 1 (45mg) plus placebo

    Drug: Placebo · Drug: 611

  • Experimental
    Cohort 2

    611 dose 2 (150mg) plus placebo

    Drug: Placebo · Drug: 611

  • Experimental
    Cohort 3

    611 dose 3 (300mg) plus placebo

    Drug: Placebo · Drug: 611

  • Experimental
    Cohort 4

    611 dose 4 (450mg) plus placebo

    Drug: Placebo · Drug: 611

  • Experimental
    Cohort 5

    611 dose 5 (600mg) plus placebo

    Drug: Placebo · Drug: 611

Interventions

  • DrugPlacebo

    placebo as a single SC injection on Day 1;

  • Drug611

    611 as a single SC injection on Day 1;

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With TEAEs

    Incidence of treatment-emergent adverse events (TEAEs) will be summarized by SOC and PT for each treatment group, and also be summarized by severity and association with the study treatments.

    Time frame: up to 71days (90 days for Cohorts 1 and 2)

Secondary outcomes

  1. PK

    PK parameters not limit to Cmax

    Time frame: up to 71days (90 days for Cohorts 1 and 2)

  2. Incidence of immunogenicity

    ADA, and NAbs if ADA is positive

    Time frame: up to 71days (90 days for Cohorts 1 and 2)

07

Study locations

1 site
  • Covance Dallas Clinical Research Unit
    Dallas, Texas 75247, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Aug 2021, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2020
First posted
Aug 26, 2020
StartActual
Sep 9, 2020
Primary completionActual
Aug 13, 2021
CompletionActual
Aug 13, 2021
Last update
Nov 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04527718
Responsible party
Sponsor
First posted
Aug 26, 2020
Start date
Sep 9, 2020
Primary completion
Aug 13, 2021
Completion
Aug 13, 2021
Last update
Nov 10, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camtarkibart

Start the discussion